期刊
HEALTHCARE
卷 11, 期 11, 页码 -出版社
MDPI
DOI: 10.3390/healthcare11111532
关键词
COVID-19; tozinameran; elasomeran; BNT162b2; mRNA-1273; systematic review; meta-analysis
This research aimed to evaluate the efficacy and safety of tozinameran and elasomeran in preventing COVID-19 in patients aged 16 and above. The meta-analysis of 8 RCTs showed that both vaccines were effective in preventing COVID-19 but were associated with a higher rate of adverse events compared to placebo.
Background: The objective of this research was to test the efficacy and safety profile of tozinameran (30 mu g, BNT162b2, Pfizer, BioNTech) and elasomeran (100 mu g, mRNA-1273, Moderna) in COVID-19 prevention in >= 16-year-old patients vaccinated with two doses. Methods: A meta-analysis of the literature was conducted using the MEDLINE and EMBASE databases, following inclusion and exclusion criteria. Eight RCTs have been selected. The results were presented using the risk ratio (RR) with a 95% confidence interval (CI). A fixed-effect model or random-effect model was applied based on the heterogeneity of the results. Results: BNT162b2 and mRNA-1273 vaccines are efficient in preventing COVID-19 in comparison to a placebo (MH, RR 0.08 [0.07, 0.09] p < 0.00001 (95% CI)). It was found that administering the vaccines BNT162b2 and mRNA-1273 was associated with a higher proportion of adverse events in comparison to the placebo (IV, RR 2.14 [1.99, 2.29] p < 0.00001 (95% CI)). Administering the vaccines BNT162b2 and mRNA-1273 was associated with a higher proportion of serious adverse events in comparison to the placebo (MH, RR 0.98 [0.89, 1.08] p = 0.68 (95% CI)). Conclusions: Tozinameran and elasomeran are effective and safe in preventing the occurrence of COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据